1. FDA OKs an eighth use for JNJ’s Xarelto — Roche’s Rituxan shows superiority in autoimmune skin condition — Sun Pharma launches dry eye disease treatment in US — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

STRYKER BUYS NOVADAQ!

Discussion in 'Novadaq' started by anonymous, Jun 19, 2017 at 3:21 PM.

  1. anonymous

    anonymous Guest

    Oh man you guys don't know Stryker! For those who think this is an opportunity to work for Stryker I will tell you that it will not be for most.
    Unfortunately, they will chew the reps up and spit them out!

    It is a pretty toxic environment.
    At Christmas parties, you and your colleagues will feast upon the flesh of your first newborns.
    Ok, I'm exaggerating, but not by much!

    Stryker already has a licensing agreement to use your technology in their 1588 system.
    The only reason Stryker is interested in purchasing your ICG technology is to prevent Novadaq from making similar licensing agreements with other video vendors on the market. For example, Olympus, Arthrex etc. I believe Karl Storz has there own ICG tech. If Stryker can purchase this product, they will really stick it to the above mentioned companies.

    Also, Novadaq's market share is laughable. Novadaq can only be profitable and survive through more licensing agreements or through acquisition of Novadaq.
     
  2. anonymous

    anonymous Guest

    We have a partnership with Arthrex